Welcome to our dedicated page for Mobix Labs SEC filings (Ticker: MOBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Mobix Labs’ progress means wading through pages packed with RF engineering talk, defense export rules, and supply-chain diagrams. If finding R&D spend or a design-win update in the latest 10-K feels daunting, you’re not alone.
Stock Titan solves that problem. Our AI reads every Mobix Labs annual report 10-K simplified, Mobix Labs quarterly earnings report 10-Q filing, and Mobix Labs 8-K material events explained the moment they hit EDGAR. It extracts what professionals actually need—chip sales by end-market, defense-contract exposure, pending patents—then writes a plain-English brief you can absorb in minutes. Want to follow Mobix Labs insider trading Form 4 transactions? Real-time alerts show executive stock moves before markets react, so you can monitor Mobix Labs executive stock transactions Form 4 without refreshing a spreadsheet.
Here’s what you’ll uncover on this page:
- 10-K & 10-Q—AI breakdowns of revenue by automotive, medical, and aerospace customers, plus year-over-year R&D trends.
- 8-K—Instant summaries whenever design-wins, supply-chain disruptions or leadership changes surface.
- Form 4—Mobix Labs Form 4 insider transactions real-time, helping you track buying before new product announcements.
- DEF 14A proxy statement executive compensation analysis outlining option grants tied to RF innovation milestones.
Whether you’re comparing quarter-over-quarter gross margin shifts or simply understanding Mobix Labs SEC documents with AI, every filing is here, already explained, and continuously updated. Save hours, gain clarity, and make informed decisions with data that matters.
On 28 July 2025 Norfolk Southern Corp. ("NSC") signed an Agreement and Plan of Merger with Union Pacific Corp. ("UNP"). The two-step transaction will give NSC holders 1 UNP common share + $88.82 cash for each NSC share; NSC will become a wholly-owned UNP subsidiary and its stock will be delisted from the NYSE.
Three NSC directors (including Mark George and Richard Anderson) will join the UNP board at closing. Key closing conditions include approvals from both shareholder bases, NYSE listing of the new UNP shares, clearance from the U.S. Surface Transportation Board, an effective Form S-4, and the absence of material adverse changes. Either party may terminate if the deal is not completed by 28 Jan 2028. Termination safeguards comprise a $2.5 billion fee payable by UNP for regulatory failure and a separate $2.5 billion reciprocal fee tied to board recommendation changes or superior proposals.
On 17 Jul 2025, Sage Hill Investors, LLC and its principal, Vernon Davis Grizzard III, filed Amendment No. 3 to Schedule 13G for Mobix Labs, Inc. (MOBX). The filing, triggered by ownership as of 30 Jun 2025, discloses beneficial ownership of 3,142,857 Class A shares—equal to 6.1 % of the outstanding class (CUSIP 60743G100).
The reporting persons hold sole voting power over the entire stake but only 1,642,857 shares under sole dispositive power; no shares are subject to shared voting or dispositive power. The Schedule was filed pursuant to Rule 13d-1(c), indicating a passive investment. The certification explicitly states the securities were not acquired to influence or change control of Mobix Labs.
This size places Sage Hill/Grizzard among the issuer’s largest shareholders, potentially increasing governance visibility while avoiding control-person status. No transaction, purchase price, or intent to seek board representation is described.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Mobix Labs, Inc. (Nasdaq: MOBX) filed an 8-K to disclose that on 26 June 2025 it issued a press release (Exhibit 99.1) announcing an unsolicited, non-binding stock-for-stock proposal to acquire Peraso Technologies Inc. (Nasdaq: PRSO).
Key disclosed terms:
- Mobix would issue newly-created MOBX Class A shares for every Peraso share.
- The exchange ratio is structured to deliver a 20 % premium to Peraso’s 30-day volume-weighted average closing price through 10 June 2025.
The filing is furnished under Item 7.01 (Regulation FD); therefore, it is not deemed filed for liability purposes under Section 18 of the Exchange Act. The document contains typical forward-looking-statement language that highlights execution, regulatory and market risks. No additional financial statements or pro-forma information are included.
Because the proposal is unsolicited and non-binding, completion of any transaction remains uncertain and depends on Peraso’s response, due-diligence outcomes, regulatory clearance and potential shareholder approval requirements.
FAQ
What is the current stock price of Mobix Labs (MOBX)?
What is the market cap of Mobix Labs (MOBX)?
What core products does Mobix Labs Inc offer?
In which industries does Mobix Labs Inc operate?
How does Mobix Labs Inc generate revenue?
What differentiates Mobix Labs Inc from its competitors?
How does the company ensure product reliability?
What market needs does Mobix Labs Inc address?
Does Mobix Labs Inc focus on innovation?
How does Mobix Labs Inc contribute to high-demand industries?
